⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors

Official Title: A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Anti-A5B1 Integrin Monoclonal Antibody PF-04605412 Administered Intravenously To Adult Patients With Advanced Or Metastatic Solid Tumors

Study ID: NCT00915278

Interventions

PF-04605412

Study Description

Brief Summary: Dose finding study of the MoaB PF-04605412 directed against the alpha5beta1 integrin. Main objective is to define the MTD (maximum tolerated dose) or MAD (maximum administrable dose) in cancer patients pre treated or unresponsive to standard therapies.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Pfizer Investigational Site, Philadelphia, Pennsylvania, United States

Pfizer Investigational Site, Nashville, Tennessee, United States

Pfizer Investigational Site, Nashville, Tennessee, United States

Pfizer Investigational Site, Nashville, Tennessee, United States

Pfizer Investigational Site, Tooting, London, United Kingdom

Pfizer Investigational Site, North Cheam, Surrey, United Kingdom

Pfizer Investigational Site, Sutton, Surrey, United Kingdom

Contact Details

Name: Pfizer CT.gov Call Center

Affiliation: Pfizer

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: